GSK Caps Respiratory Medications at $35 a Month
This follows AstraZeneca’s and Boehringer Ingelheim’s announcements to also cap their asthma chronic obstructive pulmonary disease drugs at $35.
GSK is the latest company to cap out-of-pocket costs at $35 monthly. for its asthma and chronic obstructive pulmonary disease (COPD) medicines. This program will be implemented no later than Jan. 1, 2025, the company said in the press release.
The medications included are:
- Advair Diskus (fluticasone propionate and salmeterol inhalation powder) to treat asthma
- Advair HFA (fluticasone propionate and salmeterol inhalation aerosol) to treat asthma
- Anoro Ellipta (umeclidinium and vilanterol inhalation powder) to treat chronic obstructive pulmonary disease
- Arnuity Ellipta (fluticasone furoate inhalation powder) to treat asthma
- Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) to treat chronic obstructive pulmonary disease
- Incruse Ellipta (umeclidinium inhalation powder) to treat chronic obstructive pulmonary disease
- Serevent Diskus (salmeterol xinafoate inhalation powder) to treat asthma and chronic obstructive pulmonary disease
- Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) to treat asthma and chronic obstructive pulmonary disease
- Ventolin HFA (albuterol sulfate inhalation aerosol) to treat chronic obstructive pulmonary disease
GSK also recently reduced the wholesale acquisition cost for Advair Diskus by an average of 50% and Advair HFA by an average of 20%.
Related: AstraZeneca to Cap Asthma and COPD Meds at $35 a Month
Related: Boehringer Ingelheim to Cap Out-of-Pocket Cost for Inhalers at $35
This follows AstraZeneca’s and Boehringer Ingelheim’s announcements to cap their respiratory medications at $35.
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
